ClinicalTrials.gg
WithdrawnNCT03673605Updated Sep 17, 2018

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

A Phase 4 interventional study of Rivaroxaban 15 mg and Warfarin in Mitral Valve Stenosis and Atrial Fibrillation, sponsored by PharmEvo Pvt Ltd. Withdrawn at 1 site in Pakistan. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-09-17.

Sponsored by PharmEvo Pvt Ltd · Phase 4, Interventional, and Treatment

Why this study was withdrawn
No patients Enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Title: Efficacy and safety of rivaroxiban compare with vitamin K antagonist warfarin in patients with atrial fibrillation and mitral stenosis among Pakistani population.

Read the detailed description

Atrial fibrillation is associated with an increase in the risk of ischemic stroke by a factor of four to five and accounts for up to 15% of strokes in persons of all ages and 30% in persons over the age of 80 years. The use of vitamin K antagonists is highly effective for stroke prevention in patients with non-valvular atrial fibrillation and is recommended for persons at increased risk. However, food and drug interactions necessitate frequent coagulation monitoring and dose adjustments, requirements that make it difficult for many patients to use such drugs in clinical practice.

Rivaroxaban is a direct factor Xa inhibitor that may provide more consistent and predictable anticoagulation than warfarin. It has been reported to prevent venous thromboembolism more effectively than enoxaparin in patients undergoing orthopedic surgery and was non-inferior to enoxaparin followed by warfarin in a study involving patients with established venous thrombosis. This trial was designed to compare once-daily oral rivaroxaban with dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation who were at moderate-to-high risk for stroke

02

Conditions studied

  • Mitral Valve Stenosis
  • Atrial Fibrillation
03

In context

Mitral Valve Stenosis

63 studies on the registry are indexed under Mitral Valve Stenosis; 23 are open to participants now.

Browse Mitral Valve Stenosis studies →

Lead sponsor

PharmEvo Pvt Ltd is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both gender
  • Age from 18 years up to 55 years
  • Rheumatic MS (Mild moderate severe) Hemodynamic ally stable patients
  • Associated AF or flutter documented on
  • Post PTMC or M com
  • Not previously enrolled in any trial or study on NOACS
  • Willing to participate

Exclusion criteria

Exclusion Criteria:

  • Rheumatic valve other than MS
  • Prosthetic Mitral Valve Surgery
  • Previous or stroke
  • Plan for valve replacement within six months
  • Pregnancy
  • History of bleeding complication
  • High Risk of bleeding complication
  • Allergic to study drug
  • Anemia (HB less than 10 g/dl)
  • Raised > 2xUNL
  • \<30ml/min
  • Not willing to participate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Drug: Rivaroxaban 15 mg

  • Active comparator
    Warfarin

    Drug: Warfarin

Interventions

  • Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.

  • Warfarin in stroke prevention in patients with Mitral Stenosis and AF.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging

    Intracranial bleeding: symptomatic hemorrhage confirmed by CT or MRI or asymptomatic hemorrhage on follow-up GRE or SWI imaging at 1 month Recurrent ischemic lesion: symptomatic ischemic stroke confirmed by relevant neuroimagings or asymptomatic recurrent ischemic lesion on follow-up or FLAIR imaging at 12 month

    Time frame: 12 months

Secondary outcomes

  1. Adverse effects/complications of Rivaroxiban as compared to Warfarin in patients with Mitral Stenosis and AF.

    Time frame: 12 months

07

Study locations

1 site
  • National Institute of Cardiovascular
    Karachi, Sindh, Pakistan
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Oct 2017, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2016
First posted
Sep 17, 2018
StartActual
Dec 30, 2016
Primary completionActual
Oct 30, 2017
CompletionActual
Dec 30, 2017
Last update
Sep 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03673605
Lead sponsor
PharmEvo Pvt Ltd
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
Dec 30, 2016
Primary completion
Oct 30, 2017
Completion
Dec 30, 2017
Last update
Sep 17, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion